Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
出版年份 2015 全文链接
标题
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 170, Issue 1, Pages 40-49
出版商
Wiley
发表日期
2015-03-30
DOI
10.1111/bjh.13380
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
- (2013) Sandra Eketorp Sylvan et al. LEUKEMIA & LYMPHOMA
- Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement
- (2013) Marcin Okroj et al. MEDICAL ONCOLOGY
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
- (2012) Andrew R. Pettitt et al. JOURNAL OF CLINICAL ONCOLOGY
- Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
- (2012) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia
- (2012) Lukáš Smolej et al. LEUKEMIA RESEARCH
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
- (2011) W. G. Wierda et al. BLOOD
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
- (2009) A Österborg et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now